PALISADE BIO INC
PALINASDAQTrading Snapshot
- Day Range
- $2.02 – $2.06
- 52-Week Range
- $0.53 – $2.86
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 173.6M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $500,000
- Last Q Revenue
- $500,000
- P/E Ratio
- -4.0
- P/S Ratio
- 742.9x
- EPS (TTM)
- $-0.15
- Dividend Yield
- 0.00%
Why Investors Own PALI
- ✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PALISADE BIO INC
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company’s lead candidate, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed...
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.